Market Intelligence, Clinical Progress, and High-Purity Reagents for Targeting the Translation Machinery in Cancer and Antiviral Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for EEF1A1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | EEF1A1 Full-Length Recombinant Protein High purity (>95%), GTP-binding competent, Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View EEF1A1 Products |
| Antigen (Mutant) | EEF1A1 Phosphomimetic Mutants (T432D, T432A) and hotspot resistance mutants Theoretical MW confirmed. For PTM mechanism and resistance profiling. |
View EEF1A1 Products |
| Gene Delivery | EEF1A1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and overexpression studies. |
View EEF1A1 Products |
| Benchmark Ab | Anti-EEF1A1 Monoclonal (Clone EF-1) Recombinant positive control for Western/IP. Cross-reactivity tested. |
View EEF1A1 Products |
| Validator | EEF1A1 siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View EEF1A1 Products |
| Paralog Selectivity | EEF1A2 Recombinant Protein For counter-screening. >90% sequence identity, distinct tissue expression. |
View EEF1A2 Products |
| Complex Partner | EEF1B2 (eEF1B2) Recombinant Protein Elongation factor complex subunit. For PPI studies. |
View EEF1B2 Products |
| Translation Network | EEF2 Recombinant Protein For combination screening and elongation network synergism. |
View EEF2 Products |
| Pathway Integration | MTOR Protein Upstream translation pathway integration for combination therapy. |
View MTOR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GTP-binding site validation & Orthosteric screening | High purity (>95%) EEF1A1 with native GTPase fold. Sequence Verified. Suitable for GTP displacement assays. |
| Post-translational modification functional analysis | Phosphomimetic mutants (T432D, T432A) and phosphorylation-deficient variants. Theoretical MW confirmed by MS. |
| Paralog selectivity (EEF1A1 vs EEF1A2) | Both Human EEF1A1 and EEF1A2 proteins available with <15% sequence divergence in critical epitopes. |
| Target engagement in lysate (CETSA) | High-concentration protein stocks (1 mg/mL) for cellular thermal shift assay validation. |
| Drug resistance surveillance | Hotspot mutant proteins with Sequence Verified identity for resistance profiling and SPR/BLI. |
| Assay noise / False positives | Endotoxin-controlled (<1 EU/µg), validated siRNA included for specificity checks. |
Live EEF1A1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The targeting of EEF1A1 represents a paradigm shift from "undruggable" traditional views to validated cancer vulnerability. As a core component of the translational elongation machinery (including the tr-type G domain for GTP binding), EEF1A1 overexpression correlates with metastasis and poor prognosis in lung, breast, and hematological malignancies. The race for EEF1A1 therapeutics is intensifying, with major players shifting focus from empirical cytotoxics to structure-based allosteric inhibitors and targeted protein degradation. Clinical-stage natural product derivatives such as Plitidepsin (PharmaMar) have established proof-of-mechanism in multiple myeloma and viral infections. As first-generation small molecules enter preclinical validation, the next wave of R&D is targeting isoform-selective modulation, dual-function inhibitors, and PROTACs that disrupt both protein synthesis and cytoskeletal remodeling.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Allosteric Small Molecule | Vividion (Bristol Myers Squibb), HotSpot Therapeutics | Solid Tumors (NSCLC, Breast) | Thermal Shift Assay (Need high-purity WT protein with stable GTPase domain) |
| PROTAC / Degrader | Arvinas, C4 Therapeutics (preclinical) | Hematological Cancers | Binary complex formation (Need target + E3 ligase proteins) |
| Molecular Glue | Monte Rosa Therapeutics | Refractory Solid Tumors | Ternary complex stabilization (Need PTM-mutant variants for selectivity) |
| Orthosteric GTP Competitor | Academic Consortiums | Metastatic Cancers | GTPase Activity Assay (Need enzymatically competent protein) |
| Natural Product Derivative | PharmaMar | Multiple Myeloma, Antiviral | Paralog Selectivity Assay (Need EEF1A1 vs EEF1A2 proteins) |
| siRNA / RNAi | Preclinical Biotechs | Lung, Breast Cancer | Target Validation (Need validated siRNA and lentivirus ORF rescue) |
Molecular Differentiation & Assay Strategy
Key Differentiation Factors
- Paralog selectivity (EEF1A1 vs EEF1A2): >90% sequence identity demands rigorous counter-screening. TarMart provides both recombinant proteins for SPR/BLI.
- Post-translational function switch: T432 phosphorylation determines actin-bundling vs translation activities. Use T432D/T432A mutants for assay differentiation.
- Resistance profiling: Pre-empt hotspot mutations with mutant protein panels.
- Ternary complex for PROTACs: High-purity EEF1A1 with correct folding enables reliable TR-FRET assays.
TarMart Product Support
| Differentiation Need | Recommended Assay | TarMart Reagent |
|---|---|---|
| Allosteric site discovery | Cysteine labeling, TMT/SILAC | WT EEF1A1 (full surface cysteines) |
| Orthosteric GTP competition | GTPase-Glo assay | Active EEF1A1 (>95% purity) |
| Functional selectivity | Actin bundling vs in vitro translation | T432D mutant (cytoskeletal) + T432A mutant (translation) |
| Degrader development | Ternary complex (TR-FRET) | Biotinylated EEF1A1 + VHL protein |
| Selectivity validation | SPR cross-reactivity | EEF1A1 + EEF1A2 + KRAS G12D protein panel |
Cross-sell Targets
- EEF1A2: Mandatory paralog for selectivity safety assessment.
- EEF1B2: Guanine nucleotide exchange factor for complex dynamics studies.
- EEF2: Elongation network partner for combination screening.
- MTOR: Upstream translation regulator for combination therapy research.
- KRAS (G12D/G12C): Structural similarity demands selectivity check to avoid RAS pathway interference.